5AM Ventures reposted this
Entrada Therapeutics reports preliminary data in healthy volunteers from Phase 1 ENTR-601-44-101 trial for Duchenne muscular dystrophy. Learn more here: https://lnkd.in/dMPZtt9a
Congratulations, Dipal and the rest of the Entrada Team! Best of luck as you head into phase 2 studies.
This is so AWESOME‼️
Excellent news for the dmd community!
Exciting times!
Innovative Leadership in Life Sciences & Technology Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies
2moCongratulations to Entrada Therapeutics on reporting preliminary data from the Phase 1 ENTR-601-44-101 trial for Duchenne muscular dystrophy. This is a promising step forward in the fight against DMD. Excited to see the continued progress and impact of your work.